Naveen Pemmaraju, MD is Professor in the Department of Leukemia and the Director for the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program at MD Anderson Cancer Center. He also serves as Executive Director, Cancer Medicine, for the MDACC Cancer Network. Dr Pemmaraju completed his training in the Osler Medical Program of Johns Hopkins Internal Medicine Residency, Barker Firm, in 2005-2008. He then completed his Heme/Onc Training at MDACC starting in 2008-2011, then stayed on as faculty and advanced in the ranks from Assistant Professor to Associate Professor and now Full Professor. He serves as Principal Investigator for several national/international clinical trials in BPDCN, MPN, and AML. Dr Pemmaraju is well known for his international leadership and his expertise in the development of novel therapeutic strategies, particularly in the fields of MPN and BPDCN. He has led several innovative clinical trials in the MPN field including in PV and MF, and most notably, he led the multicenter team in a phase I/2 clinical trial for patients with BPDCN that led to the first US FDA approved targeted agent for patients with BPDCN. He has authored/co-authored over 350+ publications in the medical literature, and he is the recipient of numerous awards, including the Gerald P. Bodey Award for Excellence in Education (2020) and Faculty Teaching Excellence Award (2023) at MDACC.